Prognostic factors and outcome of HER2+ breast cancer with CNS metastases

Giovanna Masci; Elisa Agostinetto; Laura Giordano; Giulia Bottai; Rosalba Torrisi; Agnese Losurdo; Rita De Sanctis; Piera Navarria; Marta Scorsetti; Monica Zuradelli; Fiorenza de Rose; Lorenzo Bello; Armando Santoro

doi:10.2217/fon-2019-0602

Prognostic factors and outcome of HER2+ breast cancer with CNS metastases

Giovanna Masci, Elisa Agostinetto, Laura Giordano, Giulia Bottai, Rosalba Torrisi, Agnese Losurdo, Rita De Sanctis, Piera Navarria, Marta Scorsetti, Monica Zuradelli, Fiorenza de Rose, Lorenzo Bello, Armando Santoro

Istituto Clinico Humanitas

Research output: Contribution to journal › Article › peer-review

Abstract

Aim: Trastuzumab prolongs progression-free and overall survival in HER2+ breast cancer (BC), but these are associated with increased distant recurrences and central nervous system metastases (CNSm). We retrospectively evaluated outcome and prognostic factors in CNSm and non-CNSm patients. Methods: Records of HER2+ BC treated in 2000-2017 were reviewed. Results: 283/1171 (24%) HER2+ BC patients developed metastatic disease. 109/283 patients (39%) have CNSm associated with worse prognosis and increased risk of death (hazard ratio: 4.7; 95% CI: 3.5-6.4). Prognostic factors were: number of CNSm (single vs multiple lesions; 3-year overall survival 39 vs 18%; p = 0.003); brain radiation (30 vs 14%; p < 0.001); new HER2-targeting therapies (30.6 vs 22.5%; p = 0.025). Conclusion: Prognosis of BC patients with CNSm has improved using HER2-targeting therapies but remains poor.

Original language	English
Pages (from-to)	269-279
Number of pages	11
Journal	Future oncology (London, England)
Volume	16
Issue number	7
DOIs	https://doi.org/10.2217/fon-2019-0602
Publication status	Published - Mar 2020

Keywords

Adult
Aged
Aged, 80 and over
Breast Neoplasms/metabolism
Central Nervous System Neoplasms/diagnosis
Combined Modality Therapy
Female
Humans
Middle Aged
Neoplasm Metastasis
Neoplasm Staging
Patient Outcome Assessment
Prognosis
Receptor, ErbB-2/genetics
Treatment Outcome

Access to Document

10.2217/fon-2019-0602

Fingerprint Dive into the research topics of 'Prognostic factors and outcome of HER2+ breast cancer with CNS metastases'. Together they form a unique fingerprint.

Cite this

Prognostic factors and outcome of HER2+ breast cancer with CNS metastases. / Masci, Giovanna; Agostinetto, Elisa; Giordano, Laura; Bottai, Giulia; Torrisi, Rosalba ; Losurdo, Agnese ; De Sanctis, Rita ; Navarria, Piera ; Scorsetti, Marta ; Zuradelli, Monica; de Rose, Fiorenza; Bello, Lorenzo; Santoro, Armando.

In: Future oncology (London, England), Vol. 16, No. 7, 03.2020, p. 269-279.

Research output: Contribution to journal › Article › peer-review

Masci, Giovanna ; Agostinetto, Elisa ; Giordano, Laura ; Bottai, Giulia ; Torrisi, Rosalba ; Losurdo, Agnese ; De Sanctis, Rita ; Navarria, Piera ; Scorsetti, Marta ; Zuradelli, Monica ; de Rose, Fiorenza ; Bello, Lorenzo ; Santoro, Armando. / Prognostic factors and outcome of HER2+ breast cancer with CNS metastases. In: Future oncology (London, England). 2020 ; Vol. 16, No. 7. pp. 269-279.

@article{1d760a5ee6f040829b26a90d300fadd3,

title = "Prognostic factors and outcome of HER2+ breast cancer with CNS metastases",

abstract = "Aim: Trastuzumab prolongs progression-free and overall survival in HER2+ breast cancer (BC), but these are associated with increased distant recurrences and central nervous system metastases (CNSm). We retrospectively evaluated outcome and prognostic factors in CNSm and non-CNSm patients. Methods: Records of HER2+ BC treated in 2000-2017 were reviewed. Results: 283/1171 (24%) HER2+ BC patients developed metastatic disease. 109/283 patients (39%) have CNSm associated with worse prognosis and increased risk of death (hazard ratio: 4.7; 95% CI: 3.5-6.4). Prognostic factors were: number of CNSm (single vs multiple lesions; 3-year overall survival 39 vs 18%; p = 0.003); brain radiation (30 vs 14%; p < 0.001); new HER2-targeting therapies (30.6 vs 22.5%; p = 0.025). Conclusion: Prognosis of BC patients with CNSm has improved using HER2-targeting therapies but remains poor.",

keywords = "Adult, Aged, Aged, 80 and over, Breast Neoplasms/metabolism, Central Nervous System Neoplasms/diagnosis, Combined Modality Therapy, Female, Humans, Middle Aged, Neoplasm Metastasis, Neoplasm Staging, Patient Outcome Assessment, Prognosis, Receptor, ErbB-2/genetics, Treatment Outcome",

author = "Giovanna Masci and Elisa Agostinetto and Laura Giordano and Giulia Bottai and Rosalba Torrisi and Agnese Losurdo and {De Sanctis}, Rita and Piera Navarria and Marta Scorsetti and Monica Zuradelli and {de Rose}, Fiorenza and Lorenzo Bello and Armando Santoro",

year = "2020",

month = mar,

doi = "10.2217/fon-2019-0602",

language = "English",

volume = "16",

pages = "269--279",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "7",

}

TY - JOUR

T1 - Prognostic factors and outcome of HER2+ breast cancer with CNS metastases

AU - Masci, Giovanna

AU - Agostinetto, Elisa

AU - Giordano, Laura

AU - Bottai, Giulia

AU - Torrisi, Rosalba

AU - Losurdo, Agnese

AU - De Sanctis, Rita

AU - Navarria, Piera

AU - Scorsetti, Marta

AU - Zuradelli, Monica

AU - de Rose, Fiorenza

AU - Bello, Lorenzo

AU - Santoro, Armando

PY - 2020/3

Y1 - 2020/3

N2 - Aim: Trastuzumab prolongs progression-free and overall survival in HER2+ breast cancer (BC), but these are associated with increased distant recurrences and central nervous system metastases (CNSm). We retrospectively evaluated outcome and prognostic factors in CNSm and non-CNSm patients. Methods: Records of HER2+ BC treated in 2000-2017 were reviewed. Results: 283/1171 (24%) HER2+ BC patients developed metastatic disease. 109/283 patients (39%) have CNSm associated with worse prognosis and increased risk of death (hazard ratio: 4.7; 95% CI: 3.5-6.4). Prognostic factors were: number of CNSm (single vs multiple lesions; 3-year overall survival 39 vs 18%; p = 0.003); brain radiation (30 vs 14%; p < 0.001); new HER2-targeting therapies (30.6 vs 22.5%; p = 0.025). Conclusion: Prognosis of BC patients with CNSm has improved using HER2-targeting therapies but remains poor.

AB - Aim: Trastuzumab prolongs progression-free and overall survival in HER2+ breast cancer (BC), but these are associated with increased distant recurrences and central nervous system metastases (CNSm). We retrospectively evaluated outcome and prognostic factors in CNSm and non-CNSm patients. Methods: Records of HER2+ BC treated in 2000-2017 were reviewed. Results: 283/1171 (24%) HER2+ BC patients developed metastatic disease. 109/283 patients (39%) have CNSm associated with worse prognosis and increased risk of death (hazard ratio: 4.7; 95% CI: 3.5-6.4). Prognostic factors were: number of CNSm (single vs multiple lesions; 3-year overall survival 39 vs 18%; p = 0.003); brain radiation (30 vs 14%; p < 0.001); new HER2-targeting therapies (30.6 vs 22.5%; p = 0.025). Conclusion: Prognosis of BC patients with CNSm has improved using HER2-targeting therapies but remains poor.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Breast Neoplasms/metabolism

KW - Central Nervous System Neoplasms/diagnosis

KW - Combined Modality Therapy

KW - Female

KW - Humans

KW - Middle Aged

KW - Neoplasm Metastasis

KW - Neoplasm Staging

KW - Patient Outcome Assessment

KW - Prognosis

KW - Receptor, ErbB-2/genetics

KW - Treatment Outcome

U2 - 10.2217/fon-2019-0602

DO - 10.2217/fon-2019-0602

M3 - Article

C2 - 32043375

VL - 16

SP - 269

EP - 279

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 7

ER -